Table 1

Characteristics of the RA cohort of incident statin users (N=4102)

 Age (years), mean (SD)66.6±10.4
 Women2460 (60)
RA characteristics
 RA duration at index date (months), mean (SD)19.0±25.5
 Rate of RA-related medical visits (visits/person year follow-up), mean (SD)2.5±6.7
 RA-related orthopaedic procedures (over follow-up)621 (15.1)
 Use of RA prescription medications (over follow-up)
  Traditional NSAIDs2364 (57.6)
  COX-2-selective NSAIDs1347 (32.8)
  Glucocorticosteroids1723 (42.0)
Co-morbid medical conditions
 Prior acute myocardial infarction*441 (10.8)
 Prior cerebrovascular accident*117 (2.9)
 Use of anti-hypertension medication2528 (61.6)
 Use of congestive heart failure medication1344 (32.8)
 Angina903 (22.0)
 Diabetes730 (17.8)
 Use of anti-arrhythmia medication§94 (2.3)
 Charlson comorbidity score, mean (SD)1.0±1.3
Other medications affecting cardiovascular risk
 Use of hormone replacement therapy506 (12.3)
 Use of anticoagulants266 (6.5)
  • Values represent the number (percentage) of cases unless otherwise indicated.

  • * Evaluated prior to start of follow-up (index date) since 1990 (earliest available data).

  • Evaluated over 1 year preceding start of follow-up (index date).

  • Congestive heart failure medications included cardiac glycosides or diuretics.

  • § Anti-arrhythmia medications included: adenosine, amiodarone, disopyramide, flecainide, lidocaine, mexitelene, procainamide, propafenone, digoxin or quinidine.

  • Anti-hypertension medications included: angiotensin-converting enzyme inhibitors, β-blockers, calcium channel blocking agents, angiotensin II receptor antagonists, α-adrenergic blocking agents or central α-agonists.

  • COX-2, cyclooxygenase-2; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis.